Skip to main content

Anebulo Pharmaceuticals, Inc. (ANEB)

NASDAQ: ANEB · IEX Real-Time Price · USD
6.90 -0.09 (-1.26%)
Oct 21, 2021 11:32 AM EDT - Market open
Market Cap161.08M
Revenue (ttm)n/a
Net Income (ttm)-38.46M
Shares Out13.61M
EPS (ttm)-2.83
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,580
Open7.03
Previous Close6.99
Day's Range6.90 - 7.03
52-Week Range6.31 - 9.33
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 15, 2021

About ANEB

Anebulo Pharmaceuticals is a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Our lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations. There is no approved medical treatment currently available to specifically alleviate the symptoms of cannabinoid ov...

IndustryBiotechnology
IPO DateMay 7, 2021
CEODaniel Schneeberger, M.D.
Employees2
Stock ExchangeNASDAQ
Ticker SymbolANEB
Full Company Profile

News

Anebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabi...

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from...

1 week ago - Business Wire

Overdose Unknown: How Anebulo Pharmaceuticals Is Working to Solve a Growing Marijuana Overdose Problem

Photo by Elsa Olofsson on Unsplash Many people today remain unaware of the risks an overdose of marijuana carries. In fact, some people don't believe overdosing on cannabis to be possible.

1 week ago - Benzinga

CBD-Focused Anebulo Pharma Posts Q4 & Full Year 2021 Earnings, Launching Phase 2 Cannabis Overdose Clinical Trials

Cannabinoid-focused biotech company Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) announced its financial results Wednesday for the three and 12 months ended June 30. Over the fourth quarter of fiscal 202...

4 weeks ago - Benzinga

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business Update

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxicati...

4 weeks ago - Business Wire

Anebulo Pharmaceuticals Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxicati...

1 month ago - Business Wire

Anebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from...

1 month ago - Business Wire

A Week's Worth of Actionable Cannabis Stock News

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up...

2 months ago - Schaeffers Research

Anebulo Pharmaceuticals Announces Formation of Scientific Advisory Board, Names First Two Members

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from...

2 months ago - Business Wire

Cannabinoid-Focused Anebulo Pharma Posts Q3 Earnings, On Schedule To Start Cannabis Overdose Clinical Trials

Cannabinoid-focused biotech company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) released its third-quarter fiscal 2021 financial results on Tuesday with a net loss of $555,832 or $0.04 per share.  The ...

3 months ago - Benzinga

Anebulo Pharmaceuticals Reports Recent Business Highlights and Announces Third Quarter Fiscal Year 2021 Financial Res...

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biotechnology company developing novel solutions for people suffering from can...

3 months ago - Business Wire

Anebulo Pharmaceuticals Announces Pricing of Initial Public Offering

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biotechnology company developing novel solutions for people suffering from can...

5 months ago - Business Wire

Rain Ther­a­peu­tics head­lines newest slate of IPO-bound biotechs with $100M pen­ciled in for lead on­col­o­gy pro­gram

A fresh slate of biotech IPOs has filed to go public as the calendar turns toward the second quarter.

6 months ago - Endpoints News

Anebulo Pharmaceuticals IPO Registration Document (S-1)

Anebulo Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.

6 months ago - SEC